Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 261

1.

Early detection of chemoradioresponse in esophageal carcinoma by 3'-deoxy-3'-3H-fluorothymidine using preclinical tumor models.

Apisarnthanarax S, Alauddin MM, Mourtada F, Ariga H, Raju U, Mawlawi O, Han D, Bornmann WG, Ajani JA, Milas L, Gelovani JG, Chao KS.

Clin Cancer Res. 2006 Aug 1;12(15):4590-7.

2.

[Correlation of 3'-deoxy-3'-18F-fluorothymidine uptake to cell proliferation in lung carcinoma xenografts].

Liu X, Zhou NK, Zhang JM, Liang ZY, Zheng X.

Ai Zheng. 2006 Dec;25(12):1512-6. Chinese.

PMID:
17166377
4.

3'-deoxy-3'-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography.

Barthel H, Cleij MC, Collingridge DR, Hutchinson OC, Osman S, He Q, Luthra SK, Brady F, Price PM, Aboagye EO.

Cancer Res. 2003 Jul 1;63(13):3791-8.

6.

Early detection of response to experimental chemotherapeutic Top216 with [18F]FLT and [18F]FDG PET in human ovary cancer xenografts in mice.

Jensen MM, Erichsen KD, Björkling F, Madsen J, Jensen PB, Højgaard L, Sehested M, Kjær A.

PLoS One. 2010 Sep 24;5(9):e12965. doi: 10.1371/journal.pone.0012965.

7.

Imaging colon cancer response following treatment with AZD1152: a preclinical analysis of [18F]fluoro-2-deoxyglucose and 3'-deoxy-3'-[18F]fluorothymidine imaging.

Moroz MA, Kochetkov T, Cai S, Wu J, Shamis M, Nair J, de Stanchina E, Serganova I, Schwartz GK, Banerjee D, Bertino JR, Blasberg RG.

Clin Cancer Res. 2011 Mar 1;17(5):1099-110. doi: 10.1158/1078-0432.CCR-10-1430. Epub 2011 Jan 18.

8.

Monitoring the early biologic response of esophageal carcinoma after irradiation with 18F-FLT: an in-vitro and in-vivo study.

Jiang M, Huang Q, Chen P, Ruan X, Luo Z, Zhao L, Fan W, Peng T, Sun L, Wu H.

Nucl Med Commun. 2014 Dec;35(12):1212-9. doi: 10.1097/MNM.0000000000000201.

PMID:
25192190
9.

In vivo imaging of therapy response to a novel pan-HER antibody mixture using FDG and FLT positron emission tomography.

Nielsen CH, Jensen MM, Kristensen LK, Dahlman A, Fröhlich C, Jacobsen HJ, Poulsen TT, Lantto J, Horak ID, Kragh M, Kjaer A.

Oncotarget. 2015 Nov 10;6(35):37486-99. doi: 10.18632/oncotarget.6060.

10.

[18F]FLT and [18F]FDG PET for non-invasive treatment monitoring of the nicotinamide phosphoribosyltransferase inhibitor APO866 in human xenografts.

Jensen MM, Erichsen KD, Johnbeck CB, Björkling F, Madsen J, Bzorek M, Jensen PB, Højgaard L, Sehested M, Kjær A.

PLoS One. 2013;8(1):e53410. doi: 10.1371/journal.pone.0053410. Epub 2013 Jan 4.

11.

3'-Deoxy-3'-18F-fluorothymidine PET predicts response to (V600E)BRAF-targeted therapy in preclinical models of colorectal cancer.

McKinley ET, Smith RA, Zhao P, Fu A, Saleh SA, Uddin MI, Washington MK, Coffey RJ, Manning HC.

J Nucl Med. 2013 Mar;54(3):424-30. doi: 10.2967/jnumed.112.108456. Epub 2013 Jan 22.

12.

Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG.

Chen W, Cloughesy T, Kamdar N, Satyamurthy N, Bergsneider M, Liau L, Mischel P, Czernin J, Phelps ME, Silverman DH.

J Nucl Med. 2005 Jun;46(6):945-52.

13.

Glioma proliferation as assessed by 3'-fluoro-3'-deoxy-L-thymidine positron emission tomography in patients with newly diagnosed high-grade glioma.

Ullrich R, Backes H, Li H, Kracht L, Miletic H, Kesper K, Neumaier B, Heiss WD, Wienhard K, Jacobs AH.

Clin Cancer Res. 2008 Apr 1;14(7):2049-55. doi: 10.1158/1078-0432.CCR-07-1553.

14.

Evaluation of 3'-deoxy-3'-18F-fluorothymidine for monitoring tumor response to radiotherapy and photodynamic therapy in mice.

Sugiyama M, Sakahara H, Sato K, Harada N, Fukumoto D, Kakiuchi T, Hirano T, Kohno E, Tsukada H.

J Nucl Med. 2004 Oct;45(10):1754-8.

15.

Predictive Value of Early-Stage Uptake of 3'-Deoxy-3'-18F-Fluorothymidine in Cancer Cells Treated with Charged Particle Irradiation.

Lin C, Kume K, Mori T, Martinez ME, Okazawa H, Kiyono Y.

J Nucl Med. 2015 Jun;56(6):945-50. doi: 10.2967/jnumed.114.152983. Epub 2015 Mar 12.

16.

Positron emission tomography imaging of human colon cancer xenografts in mice with [18F]fluorothymidine after TAS-102 treatment.

Lee HJ, Oh SJ, Lee EJ, Chung JH, Kim Y, Ryu JS, Kim SY, Lee SJ, Moon DH, Kim TW.

Cancer Chemother Pharmacol. 2015 May;75(5):1005-13. doi: 10.1007/s00280-015-2718-7. Epub 2015 Mar 17.

PMID:
25776904
17.

Histopathologic validation of 3'-deoxy-3'-18F-fluorothymidine PET for detecting tumor repopulation during fractionated radiotherapy of human FaDu squamous cell carcinoma in nude mice.

Yue JB, Yang J, Liu J, Lee J, Cabrera AR, Sun XD, Bai GH, Li YH, Yu JM.

Radiother Oncol. 2014 Jun;111(3):475-81. doi: 10.1016/j.radonc.2014.04.002. Epub 2014 May 8.

PMID:
24813091
18.

Ex-vivo biodistribution and micro-PET/CT imaging of 18F-FDG, 18F-FLT, 18F-FMISO, and 18F-AlF-NOTA-PRGD2 in a prostate tumor-bearing nude mouse model.

Cheng Z, Wei R, Wu C, Qing H, Jiang X, Lu H, Chen S, Li X, Xu G, Ai H.

Nucl Med Commun. 2015 Sep;36(9):914-21. doi: 10.1097/MNM.0000000000000339.

PMID:
25973694
19.

Gastric cancer growth control by BEZ235 in vivo does not correlate with PI3K/mTOR target inhibition but with [18F]FLT uptake.

Fuereder T, Wanek T, Pflegerl P, Jaeger-Lansky A, Hoeflmayer D, Strommer S, Kuntner C, Wrba F, Werzowa J, Hejna M, Müller M, Langer O, Wacheck V.

Clin Cancer Res. 2011 Aug 15;17(16):5322-32. doi: 10.1158/1078-0432.CCR-10-1659. Epub 2011 Jun 28.

20.

Imaging proliferation in human leukemia-tumor bearing mice with (18)F-FLT: Comparison with (18)F-FDG PET.

Lu L, Jiang L, Guan H, Gao Y, Lu H.

Hell J Nucl Med. 2012 Sep-Dec;15(3):206-9. doi: 10.1967/s002449910056. Epub 2012 Oct 25.

PMID:
23106052

Supplemental Content

Support Center